{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:39:14Z","timestamp":1791895154212,"version":"4.3.4"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ejpb.2023.09.015","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T11:41:14Z","timestamp":1695814874000},"page":"41-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Immunogenicity of a silica nanoparticle-based SARS-CoV-2 vaccine in mice"],"prefix":"10.1016","volume":"192","author":[{"given":"Clara","family":"Barbey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinpeng","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Billmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Stefan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romina","family":"Bester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Carnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Temperton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Heeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Protzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Breunig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5911-6233","authenticated-orcid":false,"given":"David","family":"Peterhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2023.09.015_b0005","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/s41564-020-00789-5","article-title":"Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies","volume":"5","author":"Lee","year":"2020","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.ejpb.2023.09.015_b0010","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2023.09.015_b0015","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41577-020-00480-0","article-title":"Viral targets for vaccines against COVID-19","volume":"21","author":"Dai","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejpb.2023.09.015_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2021.100252","article-title":"SARS-CoV-2 protein subunit vaccination of mice and rhesus macaques elicits potent and durable neutralizing antibody responses","volume":"2","author":"Mandolesi","year":"2021","journal-title":"Cell Reports Medicine."},{"key":"10.1016\/j.ejpb.2023.09.015_b0025","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1080\/22221751.2021.1921621","article-title":"A novel linker-immunodominant site (LIS) vaccine targeting the SARS-CoV-2 spike protein protects against severe COVID-19 in Syrian hamsters","volume":"10","author":"Zhang","year":"2021","journal-title":"Emerging Microbes Infect."},{"key":"10.1016\/j.ejpb.2023.09.015_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2020.166748","article-title":"The ACE2-binding Interface of SARS-CoV-2 Spike Inherently Deflects Immune Recognition","volume":"433","author":"Hattori","year":"2021","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejpb.2023.09.015_b0035","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.927306","article-title":"A Comprehensive Review of the Protein Subunit Vaccines Against COVID-19","volume":"13","author":"Heidary","year":"2022","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ejpb.2023.09.015_b0040","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1515\/BC.2008.064","article-title":"The coming of age of virus-like particle vaccines","volume":"389","author":"Jennings","year":"2008","journal-title":"Biol. Chem."},{"key":"10.1016\/j.ejpb.2023.09.015_b0045","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.copbio.2007.10.013","article-title":"Virus-like particles\u2014universal molecular toolboxes","volume":"18","author":"Ludwig","year":"2007","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.ejpb.2023.09.015_b0050","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/COH.0000000000000366","article-title":"Particle-based delivery of the HIV envelope protein","volume":"12","author":"Asbach","year":"2017","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.ejpb.2023.09.015_b0055","doi-asserted-by":"crossref","first-page":"244","DOI":"10.7150\/ntno.19796","article-title":"Nanoparticle Vaccines Adopting Virus-like Features for Enhanced Immune Potentiation","volume":"1","author":"Chattopadhyay","year":"2017","journal-title":"Nanotheranostics."},{"key":"10.1016\/j.ejpb.2023.09.015_b0060","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/nmat3775","article-title":"Engineering synthetic vaccines using cues from natural immunity","volume":"12","author":"Irvine","year":"2013","journal-title":"Nature Mater."},{"key":"10.1016\/j.ejpb.2023.09.015_b0065","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jconrel.2019.11.035","article-title":"Critical design criteria for engineering a nanoparticulate HIV-1 vaccine","volume":"317","author":"Thalhauser","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2023.09.015_b0070","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41541-021-00330-7","article-title":"Protein-based antigen presentation platforms for nanoparticle vaccines","volume":"6","author":"Nguyen","year":"2021","journal-title":"npj Vaccines"},{"key":"10.1016\/j.ejpb.2023.09.015_b0075","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.vaccine.2013.11.069","article-title":"Nanoparticle vaccines","volume":"32","author":"Zhao","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2023.09.015_b0080","doi-asserted-by":"crossref","unstructured":"M.A. Swartz, S. Hirosue, J.A. Hubbell, Engineering Approaches to Immunotherapy, Sci. Transl. Med. [Internet] 2012 [cited 2023 May 17];4. Available from: https:\/\/www.science.org\/doi\/10.1126\/scitranslmed.3003763.","DOI":"10.1126\/scitranslmed.3003763"},{"key":"10.1016\/j.ejpb.2023.09.015_b0085","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1073\/pnas.0912124107","article-title":"A self-assembling peptide acting as an immune adjuvant","volume":"107","author":"Rudra","year":"2010","journal-title":"PNAS"},{"key":"10.1016\/j.ejpb.2023.09.015_b0090","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3390\/vaccines8030433","article-title":"Lipid Nanoparticle Acts as a Potential Adjuvant for Influenza Split Vaccine without Inducing Inflammatory Responses","volume":"8","author":"Shirai","year":"2020","journal-title":"Vaccines."},{"key":"10.1016\/j.ejpb.2023.09.015_b0095","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3390\/vaccines7030076","article-title":"Nanoparticle Vaccines for Inducing HIV-1 Neutralizing Antibodies","volume":"7","author":"Brinkkemper","year":"2019","journal-title":"Vaccines (basel)."},{"key":"10.1016\/j.ejpb.2023.09.015_b0100","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.cell.2019.01.046","article-title":"Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus","volume":"176","author":"Marcandalli","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.ejpb.2023.09.015_b0105","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/s41586-021-03365-x","article-title":"Quadrivalent influenza nanoparticle vaccines induce broad protection","volume":"592","author":"Boyoglu-Barnum","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ejpb.2023.09.015_b0110","doi-asserted-by":"crossref","first-page":"8855","DOI":"10.1021\/acsnano.8b02805","article-title":"Engineering a Rugged Nanoscaffold To Enhance Plug-and-Display Vaccination","volume":"12","author":"Bruun","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejpb.2023.09.015_b0115","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.tibtech.2013.09.002","article-title":"Virus-like particle-based human vaccines: quality assessment based on structural and functional properties","volume":"31","author":"Zhao","year":"2013","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.ejpb.2023.09.015_b0120","doi-asserted-by":"crossref","unstructured":"S.W. Metz, S. Tian, G. Hoekstra, X. Yi, M. Stone, K. Horvath et al., Precisely Molded Nanoparticle Displaying DENV-E Proteins Induces Robust Serotype-Specific Neutralizing Antibody Responses. Beasley DWC, editor. PLoS Negl Trop Dis. 2016;10:e0005071.","DOI":"10.1371\/journal.pntd.0005071"},{"key":"10.1016\/j.ejpb.2023.09.015_b0125","doi-asserted-by":"crossref","first-page":"5167","DOI":"10.1039\/c3nr00357d","article-title":"Mesoporous silica nanoparticles as antigen carriers and adjuvants for vaccine delivery","volume":"5","author":"Mody","year":"2013","journal-title":"Nanoscale"},{"key":"10.1016\/j.ejpb.2023.09.015_b0130","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.xphs.2019.10.059","article-title":"Presentation of HIV-1 Envelope Trimers on the Surface of Silica Nanoparticles","volume":"109","author":"Thalhauser","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.09.015_b0135","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3390\/vaccines9060642","article-title":"Augmenting the Immune Response against a Stabilized HIV-1 Clade C Envelope Trimer by Silica Nanoparticle Delivery","volume":"9","author":"Peterhoff","year":"2021","journal-title":"Vaccines."},{"key":"10.1016\/j.ejpb.2023.09.015_b0140","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejpb.2022.10.007","article-title":"Multivalent display of engineered HIV-1 envelope trimers on silica nanoparticles for targeting and in vitro activation of germline VRC01 B cells","volume":"181","author":"Peterhoff","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2023.09.015_b0145","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s15010-020-01503-7","article-title":"A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization","volume":"49","author":"Peterhoff","year":"2021","journal-title":"Infection"},{"key":"10.1016\/j.ejpb.2023.09.015_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.104076","article-title":"Omicron\u2019s binding to sotrovimab, casirivimab, imdevimab, CR3022, and sera from previously infected or vaccinated individuals","volume":"25","author":"Mader","year":"2022","journal-title":"iScience."},{"key":"10.1016\/j.ejpb.2023.09.015_b0155","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/nbt1093-1138","article-title":"Use of Peptide Libraries to Map the Substrate Specificity of a Peptide-Modifying Enzyme: A 13 Residue Consensus Peptide Specifies Biotinylation in Escherichia coli","volume":"11","author":"Schatz","year":"1993","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejpb.2023.09.015_b0160","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0022-1759(98)00204-X","article-title":"An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow","volume":"223","author":"Lutz","year":"1999","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.ejpb.2023.09.015_b0165","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/vaccines9010052","article-title":"Linear B-Cell Epitopes in Human Norovirus GII.4 Capsid Protein Elicit Blockade Antibodies","volume":"9","author":"Moeini","year":"2021","journal-title":"Vaccines."},{"key":"10.1016\/j.ejpb.2023.09.015_b0170","doi-asserted-by":"crossref","first-page":"750","DOI":"10.3390\/vaccines9070750","article-title":"Stepwise Conformational Stabilization of a HIV-1 Clade C Consensus Envelope Trimer Immunogen Impacts the Profile of Vaccine-Induced Antibody Responses","volume":"9","author":"Hauser","year":"2021","journal-title":"Vaccines."},{"key":"10.1016\/j.ejpb.2023.09.015_b0175","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.ymthe.2019.02.001","article-title":"Evaluation of a Fully Human, Hepatitis B Virus-Specific Chimeric Antigen Receptor in an Immunocompetent Mouse Model","volume":"27","author":"Festag","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejpb.2023.09.015_b0180","doi-asserted-by":"crossref","first-page":"10808","DOI":"10.1038\/s41598-019-47149-w","article-title":"Synergy of therapeutic heterologous prime-boost hepatitis B vaccination with CpG-application to improve immune control of persistent HBV infection","volume":"9","author":"Kosinska","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejpb.2023.09.015_b0185","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1016\/j.cell.2021.03.036","article-title":"SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies","volume":"184","author":"Hoffmann","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ejpb.2023.09.015_b0190","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1126\/science.272.5259.263","article-title":"In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector","volume":"272","author":"Naldini","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.ejpb.2023.09.015_b0195","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nbt0997-871","article-title":"Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo","volume":"15","author":"Zufferey","year":"1997","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejpb.2023.09.015_b0200","doi-asserted-by":"crossref","unstructured":"G. Carnell, K. Grehan, F. Ferrara, E. Molesti, N. Temperton, An Optimized Method for the Production Using PEI, Titration and Neutralization of SARS-CoV Spike Luciferase Pseudotypes. BIO-PROTOCOL [Internet]. 2017 [cited 2023 May 17];7. Available from: https:\/\/bio-protocol.org\/e2514.","DOI":"10.21769\/BioProtoc.2514"},{"key":"10.1016\/j.ejpb.2023.09.015_b0205","doi-asserted-by":"crossref","unstructured":"C. Genova, A. Sampson, S. Scott, D. Cantoni, M. Neto, E. Bentley et al., Production, Titration, Neutralisation, Storage and Lyophilisation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Lentiviral Pseudotypes. BIO-PROTOCOL [Internet]. 2021 [cited 2023 May 17];11. Available from: https:\/\/bio-protocol.org\/e4236.","DOI":"10.21769\/BioProtoc.4236"},{"key":"10.1016\/j.ejpb.2023.09.015_b0210","doi-asserted-by":"crossref","first-page":"16527","DOI":"10.1038\/s41598-018-34853-2","article-title":"Enhancing Humoral Responses Against HIV Envelope Trimers via Nanoparticle Delivery with Stabilized Synthetic Liposomes","volume":"8","author":"Tokatlian","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejpb.2023.09.015_b0215","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41586-021-03275-y","article-title":"BNT162b vaccines protect rhesus macaques from SARS-CoV-2","volume":"592","author":"Vogel","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ejpb.2023.09.015_b0220","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1126\/science.aat9120","article-title":"Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers","volume":"363","author":"Tokatlian","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.ejpb.2023.09.015_b0225","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.cell.2019.03.016","article-title":"B Cell Responses: Cell Interaction Dynamics and Decisions","volume":"177","author":"Cyster","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.ejpb.2023.09.015_b0230","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jmii.2015.05.007","article-title":"Lower levels of IgG1 in comparison with IgG2a are associated with protective immunity against Leishmania tropica infection in BALB\/c mice","volume":"50","author":"Rostamian","year":"2017","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"10.1016\/j.ejpb.2023.09.015_b0235","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nri2274","article-title":"T-cell quality in memory and protection: implications for vaccine design","volume":"8","author":"Seder","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejpb.2023.09.015_b0240","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/jmv.26320","article-title":"SARS-CoV-2 S1 is superior to the RBD as a COVID-19 subunit vaccine antigen","volume":"93","author":"Wang","year":"2021","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ejpb.2023.09.015_b0245","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.cell.2020.10.043","article-title":"Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2","volume":"183","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejpb.2023.09.015_b0250","doi-asserted-by":"crossref","first-page":"eabl6015","DOI":"10.1126\/sciadv.abl6015","article-title":"SARS-CoV-2 receptor binding domain displayed on HBsAg virus\u2013like particles elicits protective immunity in macaques","volume":"8","author":"Dalvie","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejpb.2023.09.015_b0255","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1080\/22221751.2022.2056524","article-title":"A tandem-repeat dimeric RBD protein-based covid-19 vaccine zf2001 protects mice and nonhuman primates","volume":"11","author":"An","year":"2022","journal-title":"Emerging Microbes Infect."},{"key":"10.1016\/j.ejpb.2023.09.015_b0260","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41421-021-00320-y","article-title":"RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates","volume":"7","author":"Pan","year":"2021","journal-title":"Cell Discov."},{"key":"10.1016\/j.ejpb.2023.09.015_b0265","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1038\/s41467-021-23942-y","article-title":"SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung","volume":"12","author":"Routhu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejpb.2023.09.015_b0270","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/s41392-021-00750-w","article-title":"The self-assembled nanoparticle-based trimeric RBD mRNA vaccine elicits robust and durable protective immunity against SARS-CoV-2 in mice","volume":"6","author":"Sun","year":"2021","journal-title":"Sig Transduct Target Ther."},{"key":"10.1016\/j.ejpb.2023.09.015_b0275","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.cell.2020.06.035","article-title":"A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS","volume":"182","author":"Dai","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejpb.2023.09.015_b0280","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1021\/acschembio.1c00272","article-title":"SARS-CoV-2 RBD-Tetanus Toxoid Conjugate Vaccine Induces a Strong Neutralizing Immunity in Preclinical Studies","volume":"16","author":"Valdes-Balbin","year":"2021","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejpb.2023.09.015_b0285","doi-asserted-by":"crossref","unstructured":"J.Y. Song, W.S. Choi, J.Y. Heo, J.S. Lee, D.S. Jung, S.-W. Kim et al., Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1\/2 trial. eClinicalMedicine. 2022;51:101569.","DOI":"10.1016\/j.eclinm.2022.101569"},{"key":"10.1016\/j.ejpb.2023.09.015_b0290","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijpharm.2012.04.047","article-title":"Vaccine delivery carriers: Insights and future perspectives","volume":"440","author":"Correia-Pinto","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.09.015_b0295","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jconrel.2019.04.041","article-title":"Subchronic toxicity of silica nanoparticles as a function of size and porosity","volume":"304","author":"Mohammadpour","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2023.09.015_b0300","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2147\/IJN.S39534","article-title":"The comparative immunotoxicity of mesoporous silica nanoparticles and colloidal silica nanoparticles in mice","author":"Kim","year":"2013","journal-title":"IJN."},{"key":"10.1016\/j.ejpb.2023.09.015_b0305","doi-asserted-by":"crossref","first-page":"23466","DOI":"10.1021\/acsami.7b06024","article-title":"Silica Nanoparticle as a Lymph Node Targeting Platform for Vaccine Delivery","volume":"9","author":"An","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.ejpb.2023.09.015_b0310","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1152\/japplphysiol.00389.2006","article-title":"A sensitive in vivo model for quantifying interstitial convective transport of injected macromolecules and nanoparticles","volume":"101","author":"Reddy","year":"2006","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.ejpb.2023.09.015_b0315","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0005-2736(97)00122-3","article-title":"Lymphatic uptake and biodistribution of liposomes after subcutaneous injection","volume":"1328","author":"Oussoren","year":"1997","journal-title":"Biochim. Biophys. Acta (BBA) \u2013 Biomembr."},{"key":"10.1016\/j.ejpb.2023.09.015_b0320","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.smim.2007.11.007","article-title":"Lymphatic drainage function and its immunological implications: From dendritic cell homing to vaccine design","volume":"20","author":"Swartz","year":"2008","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.ejpb.2023.09.015_b0325","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.addr.2011.05.018","article-title":"The role of the lymphatic system in vaccine trafficking and immune response","volume":"63","author":"Pal","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2023.09.015_b0330","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jconrel.2006.01.006","article-title":"In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles","volume":"112","author":"Reddy","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2023.09.015_b0335","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/chem.201803174","article-title":"Bioconjugation with Maleimides: A Useful Tool for Chemical Biology","volume":"25","author":"Ravasco","year":"2019","journal-title":"Chem Eur J"},{"key":"10.1016\/j.ejpb.2023.09.015_b0340","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1021\/bc7002499","article-title":"Efficient Site-Specific Labeling of Proteins via Cysteines","volume":"19","author":"Kim","year":"2008","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejpb.2023.09.015_b0345","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ddtec.2018.07.002","article-title":"Minireview: Addressing the retro-Michael instability of maleimide bioconjugates","volume":"30","author":"Szijj","year":"2018","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.ejpb.2023.09.015_b0350","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nri778","article-title":"Effector and memory T-cell differentiation: implications for vaccine development","volume":"2","author":"Kaech","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejpb.2023.09.015_b0355","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3389\/fonc.2018.00404","article-title":"Interactions Between Nanoparticles and Dendritic Cells: From the Perspective of Cancer Immunotherapy","volume":"8","author":"Jia","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejpb.2023.09.015_b0360","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1126\/science.1138963","article-title":"The Vaccine Adjuvant Monophosphoryl Lipid A as a TRIF-Biased Agonist of TLR4","volume":"316","author":"Mata-Haro","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.ejpb.2023.09.015_b0365","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1007\/s00018-008-8228-6","article-title":"Putting endotoxin to work for us: Monophosphoryl lipid A as a safe and effective vaccine adjuvant","volume":"65","author":"Casella","year":"2008","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejpb.2023.09.015_b0370","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1073\/pnas.1117194109","article-title":"Polyfunctional responses by human T cells result from sequential release of cytokines","volume":"109","author":"Han","year":"2012","journal-title":"PNAS"},{"key":"10.1016\/j.ejpb.2023.09.015_b0375","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nbt.3187","article-title":"COMPASS identifies T-cell subsets correlated with clinical outcomes","volume":"33","author":"Lin","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejpb.2023.09.015_b0380","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41586-021-03841-4","article-title":"Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine","volume":"597","author":"Oberhardt","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ejpb.2023.09.015_b0385","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.medj.2021.04.003","article-title":"Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset","volume":"2","author":"Kalimuddin","year":"2021","journal-title":"Med."},{"key":"10.1016\/j.ejpb.2023.09.015_b0390","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1038\/s41423-021-00750-4","article-title":"Activation or exhaustion of CD8+ T cells in patients with COVID-19","volume":"18","author":"Rha","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.ejpb.2023.09.015_b0395","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/ni.1715","article-title":"Cytokine-secreting follicular T cells shape the antibody repertoire","volume":"10","author":"Reinhardt","year":"2009","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ejpb.2023.09.015_b0400","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection","volume":"27","author":"Feng","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejpb.2023.09.015_b0405","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejpb.2023.09.015_b0410","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123002588?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123002588?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:52:53Z","timestamp":1760547173000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641123002588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":82,"alternative-id":["S0939641123002588"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.09.015","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity of a silica nanoparticle-based SARS-CoV-2 vaccine in mice","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}